NYSE American - Nasdaq Real Time Price USD

MAIA Biotechnology, Inc. (MAIA)

Compare
3.2500 +0.0700 (+2.18%)
As of 9:32 AM EST. Market Open.
Loading Chart for MAIA
DELL
  • Previous Close 3.1800
  • Open 3.3000
  • Bid 3.2700 x 1200
  • Ask 3.3300 x 800
  • Day's Range 3.2336 - 3.2900
  • 52 Week Range 0.8200 - 5.9900
  • Volume 125,311
  • Avg. Volume 96,334
  • Market Cap (intraday) 77.892M
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) --
  • EPS (TTM) -1.6200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

maiabiotech.com

13

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MAIA

View More

Performance Overview: MAIA

Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MAIA
177.78%
S&P 500
24.79%

1-Year Return

MAIA
50.46%
S&P 500
36.34%

3-Year Return

MAIA
20.73%
S&P 500
46.16%

5-Year Return

MAIA
20.73%
S&P 500
46.16%

Compare To: MAIA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MAIA

View More

Valuation Measures

Annual
As of 11/6/2024
  • Market Cap

    76.21M

  • Enterprise Value

    64.64M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    24.10

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -107.11%

  • Return on Equity (ttm)

    -559.56%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -28.08M

  • Diluted EPS (ttm)

    -1.6200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.58M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -8.81M

Research Analysis: MAIA

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: MAIA

People Also Watch